ATX 559
Alternative Names: ATX-559Latest Information Update: 05 Nov 2024
Price :
$50 *
At a glance
- Originator Accent Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action DHX9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 Oct 2024 Phase-I clinical trials in Solid tumours (Locally recurrent, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06625515)
- 24 Oct 2024 Accent Therapeutics plans a phase I/II trial for Solid tumours (Late-stage disease, Metastatic disease, Recurrent) in USA (PO, Tablet) in Q4 2024 (NCT06625515)
- 24 Oct 2024 US FDA approves IND application for ATX 559 in Solid tumours